Diabetic neuropathy defeated 1st preview- sokhna cycle meeting


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Diabetic neuropathy defeated 1st preview- sokhna cycle meeting

  2. 2. Neuropathy… what is it? Pain arising from injury or abnormal nervous system activity. It might be central, peripheral, or both. It might occur without physical or chemical stimuli.
  3. 3. Classification of neuropathy  Mononeuropathy - involvement of a single nerve. Like: carpal tunnel syndrome.  Multiple mononeuropathy - two or more nerves individually affected.  Polyneuropathy - generalized involvement of peripheral nerves. Like: diabetic neuropathy.
  4. 4. Diabetic neuropathy Diabetic neuropathiy is a neuropathic disorder that’s associated with diabetes mellitus. These conditions are thought to result from diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum) in addition to macrovascular conditions. It affects all peripheral neuropathy including motor neurons and autonomic nervous system. therefore can affect all organs and systems. The most common of all the late complications of diabetes mellitus
  5. 5. Risk factors Poor glycaemic control Long duration Age Height Excessive alcohol Smoking Duration of diabetes Hypertension
  6. 6. STAGING 1. No-no symptoms or signs of neuropathy 2. N1-asymptomatic,signs of neuropathy 3. N2-symptomatic neuropathy 4. N3-disabling polyneuropathy
  7. 7. Symptoms  Numbness or feeling of walking in cotton  Sharp shooting or stabbing pain  Tingling pins & needles  Hot or cold sensation  Allodynia  Cramps
  8. 8. Treatment  Prevention is the best form of treatment.  Pain control  Treatment of secondary depression  Good diabetic control
  9. 9. SYMPTOMATIC TREATMENT • PHYSICAL APPROACH • PHARMACOLOGICAL • Proper footwear • NSAIDS • Foot care • Antidepressants • Nocturnal splint • Anticonvulsants • physiotherapy
  10. 10. ANTICONVULSANTS  Carbamezipine , Gabapentin , pregabaline are often used.  Used alone or as add on therapy to tricyclics.  Well tolerated.  Carbamezipine: 200-600 mg/day  Gabapentin: 900-3600 mg/day  Pregabaline: 75-300 mg/day
  11. 11. Tegretol (Carbamazepine)(CBZ)  Carbamazepine was discovered by chemist Walter Schindler at J.R. Geigy AG (now part of Novartis) in Basel, Switzerland, in 1953. Schindler then synthesized the drug in 1960, before its anti-epileptic properties had been discovered.  Carbamazepine was first marketed as a drug to treat trigeminal neuralgia (formerly known as tic douloureux) in 1962. It has been used as an anticonvulsant and antiepileptic in the UK since 1965, and has been approved in the U.S. since 1974.  It was first used to control mania at 1971.
  12. 12. Indications It’s used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. It is also used off-label for a variety of indications, including  Attention-deficit hyperactivity disorder (ADHD),  Schizophrenia, phantom limb syndrome,  Complex regional pain syndrome,  Paroxysmal extreme pain disorder,  Neuromyotonia,  intermittent explosive disorder,  borderline personality disorder,  post-traumatic stress disorder.
  13. 13. PharmacokineticsBioavailability 80 % (CR tab is less by 15% than other forms)Protein binding 76 % Hepatic by CYP3A4 to active epoxideMetabolism from (10,11 epoxide)Half-life (25-65) hours 72 % in urine (2-3) % unchangedExcretion 28 % in fecesTherapeutic range (17-50) ngm/mlSaliva conc. (20-30) %(Compared with plasma conc.)Breast milk conc. (25-60) %(Compared with plasma conc.)Placental barriers Cross Syrup 2 hoursPPCReache Conv. tab 12 hours d after CR tab 24 hours (CR is less by 25% than conv. tabs). Single dose 36 hours T1/2 Multiple doses 16-24 hours
  14. 14. Mechanism of action The mechanism of action of carbamazepine and its derivatives is relatively well understood. Carbamazepine stabilizes the inactivated state of Voltage-gated sodium channels, making fewer of these channels available to subsequently open. This leaves the affected cells less excitable until the drug dissociates. Carbamazepine has also been shown to potentiate GABA receptors made up of alpha1, beta2, gamma2 subunits
  15. 15. Tegretol interactions
  16. 16. Forms & Concentrations